IN2012DN02763A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02763A IN2012DN02763A IN2763DEN2012A IN2012DN02763A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A IN 2763DEN2012 A IN2763DEN2012 A IN 2763DEN2012A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A
- Authority
- IN
- India
- Prior art keywords
- disease
- kinase activity
- lrrk2 kinase
- larly
- particu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particu¬larly Parkinson's disease and Alzheimer's disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24655009P | 2009-09-29 | 2009-09-29 | |
CN2010001334 | 2010-09-02 | ||
PCT/CN2010/001501 WO2011038572A1 (en) | 2009-09-29 | 2010-09-27 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02763A true IN2012DN02763A (en) | 2015-09-18 |
Family
ID=43825509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2763DEN2012 IN2012DN02763A (en) | 2009-09-29 | 2010-09-27 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8778939B2 (en) |
EP (1) | EP2483254B1 (en) |
JP (1) | JP5752691B2 (en) |
KR (1) | KR20120081609A (en) |
AU (1) | AU2010302842B2 (en) |
BR (1) | BR112012006859A2 (en) |
CA (1) | CA2775753A1 (en) |
EA (1) | EA021437B1 (en) |
ES (1) | ES2512727T3 (en) |
IL (1) | IL218674A (en) |
IN (1) | IN2012DN02763A (en) |
MX (1) | MX2012003778A (en) |
SG (1) | SG179120A1 (en) |
WO (1) | WO2011038572A1 (en) |
ZA (1) | ZA201201877B (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3075730B1 (en) | 2010-06-04 | 2018-10-24 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
US9365551B2 (en) * | 2010-09-02 | 2016-06-14 | Glaxo Group Limited | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors |
HUE037844T2 (en) | 2010-11-10 | 2018-09-28 | Genentech Inc | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
CN103702665B (en) * | 2011-05-03 | 2016-08-17 | 幸讬制药公司 | For inflammation and the compound of immune-related uses |
RU2637936C2 (en) | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Inhibitors of lrrk2 kinases activity |
US9096609B2 (en) | 2011-09-30 | 2015-08-04 | Ipsen Pharma S.A.S. | Macrocyclic LRRK2 kinase inhibitors |
CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
BR112014011219B1 (en) | 2011-11-29 | 2022-08-23 | Genentech, Inc. | AMINOPYRIMIDINE DERIVATIVES, THEIR USES, AND PHARMACEUTICAL COMPOSITION |
US9145402B2 (en) * | 2011-11-29 | 2015-09-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
AR089182A1 (en) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 |
WO2013079496A1 (en) | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
ES2637245T3 (en) | 2012-06-29 | 2017-10-11 | Pfizer Inc. | New 4- (substituted amino) -7H-pyrrolo [2,3-d] pyrimidines as LRRK2 inhibitors |
PT2994454T (en) * | 2013-12-09 | 2019-04-02 | Unichem Lab Ltd | An improved process for the preparation of (3r,4r)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine |
WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
MX367370B (en) * | 2014-01-29 | 2019-08-16 | Glaxosmithkline Ip Dev Ltd | Compounds. |
AU2015210554A1 (en) | 2014-01-29 | 2016-07-07 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
BR112016022879A2 (en) * | 2014-03-31 | 2017-10-10 | Univ Columbia | histone acetyltransferase activators and uses thereof |
US10058559B2 (en) | 2014-05-15 | 2018-08-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
RU2712192C2 (en) | 2014-07-31 | 2020-01-24 | Басф Се | Method of producing pyrazoles |
CN105348182B (en) * | 2014-08-24 | 2018-04-13 | 复旦大学 | 2 alkoxy benzene formyl arylamine class compounds and its medicinal usage |
DK3194405T3 (en) | 2014-09-17 | 2019-04-15 | Oncodesign Sa | MACROCYCLIC LRRK2 KINase INHIBITORS |
CA2971413A1 (en) | 2014-12-16 | 2016-06-23 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
BR122019027518B8 (en) * | 2015-05-11 | 2021-04-13 | Basf Se | processes for the preparation of a compound, dichloropyridazine amine compound and mixture of dichloropyridazine amine compound |
KR102585412B1 (en) * | 2015-05-11 | 2023-10-05 | 바스프 에스이 | Process for preparing 4-amino-pyridazines |
MX2017016231A (en) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors. |
US10428062B2 (en) | 2015-08-12 | 2019-10-01 | Axovant Sciences Gmbh | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors |
CN108137586B (en) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | Novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as LRRK2 inhibitors |
BR112019000569A2 (en) | 2016-07-12 | 2019-04-24 | Bayer Cropscience Aktiengesellschaft | bicyclic compounds as pesticides |
WO2018082964A1 (en) | 2016-11-04 | 2018-05-11 | Basf Se | Process for the production of pyridazinyl-amides in a one-pot synthesis |
US10858367B2 (en) | 2017-01-25 | 2020-12-08 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
CN110678182B (en) * | 2017-02-24 | 2022-08-23 | 大邱庆北尖端医疗产业振兴财团 | Pharmaceutical composition containing a compound capable of penetrating the blood-brain barrier as an active ingredient for preventing or treating brain cancer |
KR101990739B1 (en) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier |
KR101990738B1 (en) | 2018-07-24 | 2019-06-19 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier |
KR101992059B1 (en) | 2018-08-23 | 2019-06-21 | 재단법인 대구경북첨단의료산업진흥재단 | Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier |
CN114555595B (en) | 2019-08-30 | 2023-12-26 | Tsd生命科学有限公司 | Imidazopyridine derivative and pharmaceutical composition containing same as active ingredient |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5449691A (en) * | 1991-12-31 | 1995-09-12 | Sterling Winthrop Inc. | 3,4-disubstituted anilines-immunomodulating agents |
CZ61098A3 (en) | 1995-08-30 | 1998-06-17 | Bayer Aktiengesellschaft | Amides of acylaminosalicylic acid as preparations for fighting pest, process of their preparation and intermediates for their preparation |
PH11998001072B1 (en) | 1997-05-07 | 2006-11-21 | Univ Pittsburgh | Inhibitors of protein isoprenyl transferases |
EP1014962A4 (en) | 1997-06-26 | 2007-06-27 | Lilly Co Eli | Antithrombotic agents |
EP1072263A4 (en) | 1998-03-26 | 2004-03-31 | Japan Tobacco Inc | Amide derivatives and nociceptin antagonists |
EP1263756B1 (en) | 2000-03-17 | 2004-02-25 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
DE10159453A1 (en) | 2001-12-04 | 2003-06-18 | Merck Patent Gmbh | Use of 1-phenyl-oxazolidin-2-one compounds as a protease |
AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
US20060235035A1 (en) | 2002-04-09 | 2006-10-19 | 7Tm Pharma A/S | Novel methoxybenzamibe compounds for use in mch receptor related disorders |
WO2004099170A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
WO2004099127A1 (en) | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
EP1710233A4 (en) * | 2004-01-28 | 2009-07-15 | Kissei Pharmaceutical | Novel benzofuran derivative, medicinal composition containing the same, and uses of these |
WO2006003923A1 (en) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | Substituted benzene compound |
US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
US20060276496A1 (en) | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
TW200800872A (en) * | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
JP2007176799A (en) | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | Medicine comprising substituted benzene compound |
MX2008011136A (en) | 2006-03-07 | 2008-09-08 | Squibb Bristol Myers Co | Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors. |
JP2009535318A (en) | 2006-04-28 | 2009-10-01 | トランステック ファーマ,インコーポレイティド | Benzamide glucokinase activator |
NZ577109A (en) * | 2006-12-15 | 2011-12-22 | Glaxo Group Ltd | Benzamide derivatives as ep4 receptor agonists |
WO2009030270A1 (en) * | 2007-09-03 | 2009-03-12 | Novartis Ag | Dihydroindole derivatives useful in parkinson's disease |
GB0722680D0 (en) | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
WO2010048559A2 (en) | 2008-10-24 | 2010-04-29 | Calcimedica Inc. | Phenylpyrazole inhibitors of store operated calcium release |
-
2010
- 2010-09-27 IN IN2763DEN2012 patent/IN2012DN02763A/en unknown
- 2010-09-27 KR KR1020127010852A patent/KR20120081609A/en active IP Right Grant
- 2010-09-27 EP EP10819801.1A patent/EP2483254B1/en active Active
- 2010-09-27 CA CA2775753A patent/CA2775753A1/en not_active Abandoned
- 2010-09-27 WO PCT/CN2010/001501 patent/WO2011038572A1/en active Application Filing
- 2010-09-27 ES ES10819801.1T patent/ES2512727T3/en active Active
- 2010-09-27 JP JP2012531212A patent/JP5752691B2/en not_active Expired - Fee Related
- 2010-09-27 MX MX2012003778A patent/MX2012003778A/en active IP Right Grant
- 2010-09-27 SG SG2012017760A patent/SG179120A1/en unknown
- 2010-09-27 AU AU2010302842A patent/AU2010302842B2/en not_active Ceased
- 2010-09-27 US US13/498,975 patent/US8778939B2/en not_active Expired - Fee Related
- 2010-09-27 EA EA201270480A patent/EA021437B1/en not_active IP Right Cessation
- 2010-09-27 BR BR112012006859A patent/BR112012006859A2/en not_active IP Right Cessation
-
2012
- 2012-03-14 ZA ZA2012/01877A patent/ZA201201877B/en unknown
- 2012-03-15 IL IL218674A patent/IL218674A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL218674A (en) | 2015-11-30 |
BR112012006859A2 (en) | 2019-09-24 |
ES2512727T3 (en) | 2014-10-24 |
SG179120A1 (en) | 2012-05-30 |
ZA201201877B (en) | 2012-11-28 |
US20120184553A1 (en) | 2012-07-19 |
EA021437B1 (en) | 2015-06-30 |
IL218674A0 (en) | 2012-05-31 |
US8778939B2 (en) | 2014-07-15 |
AU2010302842B2 (en) | 2014-05-08 |
JP5752691B2 (en) | 2015-07-22 |
EP2483254A1 (en) | 2012-08-08 |
WO2011038572A1 (en) | 2011-04-07 |
KR20120081609A (en) | 2012-07-19 |
JP2013505969A (en) | 2013-02-21 |
EA201270480A1 (en) | 2013-08-30 |
EP2483254B1 (en) | 2014-08-13 |
MX2012003778A (en) | 2012-06-01 |
CA2775753A1 (en) | 2011-04-07 |
EP2483254A4 (en) | 2013-02-27 |
AU2010302842A1 (en) | 2012-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02763A (en) | ||
TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
MX2009000333A (en) | Pyrrolopyrimidines for pharmaceutical compositions. | |
TW200800968A (en) | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | |
MX2012007273A (en) | Pteridinones as inhibitors of polo - like kinase. | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
BR112012006858A2 (en) | method of improving flexographic printing plate printing performance | |
MX2013001970A (en) | Pyrrolopyrimidine compounds and uses thereof. | |
MX2011011661A (en) | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750. | |
UA94944C2 (en) | 2,4-diamino pyrimidines as cell cycle kinase inhibitors | |
MX342177B (en) | Macrocyclic lrrk2 kinase inhibitors. | |
WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
MX2009010407A (en) | Fluorinated derivatives of deferiprone. | |
TNSN07383A1 (en) | 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands | |
MX2012004548A (en) | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system. | |
AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
TW200726763A (en) | Novel compound | |
MY150931A (en) | Substituted oxazolidinones and their use | |
MX2010009837A (en) | Thiazolyl-dihydro-indazoles. | |
TN2011000531A1 (en) | 5- alkynyl - pyridines | |
WO2011008675A3 (en) | Catecholamine compounds, compositions, and formulations, and methods of using the same | |
WO2009151495A3 (en) | Oxazole compounds, compositions and methods of use | |
TN2012000370A1 (en) | 5-alkynyl pyrimidines and their use as kinase inhibitors |